Yasaka, Masahiro http://orcid.org/0000-0002-1163-8355
Yokota, Hiroyuki
Suzuki, Michiyasu
Asakura, Hidesaku
Yamane, Teiichi
Ogi, Yukako
Kimoto, Takaaki
Nakayama, Daisuke
Clinical trials referenced in this document:
Documents that mention this clinical trial
Idarucizumab for Emergency Reversal of the Anticoagulant Effects of Dabigatran: Final Results of a Japanese Postmarketing Surveillance Study
https://doi.org/10.1007/s40119-023-00333-6
Funding for this research was provided by:
Nippon Boehringer Ingelheim Co., Ltd.
Article History
Received: 21 June 2023
Accepted: 11 September 2023
First Online: 17 October 2023
Declarations
:
: Masahiro Yasaka has received lecture, advisory, and travel fees from Bristol-Myers Squibb, Nippon Boehringer Ingelheim, Bayer, Daiichi Sankyo, and CSL Behring, as well as scholarship funds or non-restricted grants from Nippon Boehringer Ingelheim. Hiroyuki Yokota has received lecture fees, consulting fees, and grants from Herusu-Shuppan, MEDIC MEDIA, MEDICAL VIEW, Stryker Japan, and UCB Japan. Michiyasu Suzuki has received lecture fees from Nippon Boehringer Ingelheim and CSL Behring. Hidesaku Asakura has received lecture fees from Bristol-Myers Squibb, Pfizer, Daiichi Sankyo, Bayer, Nippon Boehringer Ingelheim; scholarships from Pfizer, Daiichi Sankyo, Nippon Boehringer Ingelheim, CSL Behring; and grants from Bristol-Myers Squibb. Teiichi Yamane has received lecture and consulting fees from Daiichi Sankyo, Nippon Boehringer Ingelheim, Abbott Japan, Bristol-Myers Squibb, Bayer Pharmaceutical Company, and Medtronic Japan. Yukako Ogi and Daisuke Nakayama are employees of Nippon Boehringer Ingelheim. Takaaki Kimoto is an employee of the EPS Corporation. Current affiliation for Masahiro Yasaka: Department of Cerebrovascular Medicine, Fukuoka Neurosurgical Hospital, 5-3-15 Osa, Minami-ku, Fukuoka 811–1313, Japan.
: This study was conducted according to the Declaration of Helsinki (1964 and its later amendments). The study also complied with Japanese Good Post-marketing Study Practice regulations, and the protocol was approved by the Japanese Ministry of Health, Labour and Welfare. Anonymous data were collected from clinical settings, and thus it was not necessary to obtain informed consent from the patients. The medical institutions that agreed to provide anonymized data signed a contract with the sponsor (Nippon Boehringer Ingelheim Co., Ltd.). This study is registered with ClinicalTrials.gov (NCT02946931).